Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 19 4s 3?
Displaying drugs 8201 - 8225 of 12202 in total
Experimental
Matched Name: … [N-[N-(4-Methoxy-2,3,6-trimethylphenylsulfonyl)-L-aspartyl]-D-(4-amidino-phenylalanyl)]-piperidine …
Matched Iupac: … (3S)-3-{[(2R)-3-(4-carbamimidoylphenyl)-1-oxo-1-(piperidin-1-yl)propan-2-yl]carbamoyl}-3-(4-methoxy-2,3,6 …
Experimental
Matched Name: … (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine …
Matched Iupac: … (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethan-1-amine …
Experimental
Matched Mixtures name: … BION 3 FILM COATED TABLET …
Experimental
JNJ-38877605 has been used in trials studying the treatment of Neoplasms.
Investigational
Matched Iupac: … 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline …
Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics. The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics.
Investigational
Ongericimab is under investigation in clinical trial NCT05325203 (A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (Hefh).).
Investigational
Matched Synonyms: … Immunoglobulin g4, anti-(neural apoptosis-regulated convertase 1) (human monoclonal js002 .gamma.4-chain …
MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema.
Investigational
JNJ-39220675 has been used in trials studying the treatment of Allergic Rhinitis.
Investigational
Matched Iupac: … 1-cyclobutyl-4-[6-(4-fluorophenoxy)pyridine-3-carbonyl]-1,4-diazepane …
Investigational
Matched Iupac: … 6-{difluoro[6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline …
Investigational
Dehydroascorbic acid is made from the oxidation of ascorbic acid. This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid. Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. In the body,...
Experimental
Experimental
Matched Iupac: … (2R,3R,4S,5S,6R)-2-[(dimethoxyphosphoryl)amino]-6-(hydroxymethyl)oxane-3,4,5-triol …
Experimental
Matched Iupac: … (2R,3R,4S,5R,6S)-2-methyl-6-(2-nitrophenoxy)oxane-3,4,5-triol …
Experimental
Matched Iupac: … 4,5-dimethyl-2-[(1R,2S,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl]phenol …
A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]
Experimental
Matched Iupac: … (5Z)-7-[(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept- …
Investigational
Matched Synonyms: … -d-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)- ... -d-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-l-asparagine …
Matched Iupac: … (2S)-2-amino-3-({1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1,2-dihydropyrimidin ... -4-yl}carbamoyl)propanoic acid …
Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.
Investigational
Matched Iupac: … N-[(1-butylpiperidin-4-yl)methyl]-2H,3H,4H-[1,3]oxazino[3,2-a]indole-10-carboxamide …
Matched Description: … Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist. …
Experimental
Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).
Investigational
Matched Iupac: … 1-(2-hydroxyethyl)-N-(4-methanesulfonylphenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide …
Pemivibart (Pemgarda) is a half life-extended monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. It received emergency use authorization (EUA) by the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.
Investigational
AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.
Investigational
Displaying drugs 8201 - 8225 of 12202 in total